IP Library › Granted Patent US 7,820,687
Granted Patent B2
US 7,820,687 · App. 12/505,383 · Granted Oct 26, 2010

Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by VLA-4

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,820,687
App. No.
12/505,383
Granted
Oct 26, 2010
Kind
B2
Abstract

Disclosed are compounds, which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a human or animal subject such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, Crohn's disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

Claims (41)

1. A method for treating a disease in a patient said disease selected from the group consisting of asthma, inflammatory bowel disease, ulcerative colitis, Crohn's disease, multiple sclerosis, rheumatoid arthritis, tumor metastasis, graft versus host disease, and organ or tissue rejection, which method comprises administering to the patient a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of one or more of a compound of formula I:

wherein:

R 1 is selected from the group consisting of C 1 to C 4 alkyl and C 1 to C 4 haloalkyl; and

R 2 is selected from the group consisting of C 1 to C 4 alkyl, C 2 to C 4 alkenyl, C 2 to C 4 alkynyl, and C 3 -C 6 cycloalkyl

or a pharmaceutically acceptable salt or ester of the —COOH group thereof.

2. The method of claim 1 , wherein the disease is asthma.

3. The method of claim 1 wherein the disease is Crohn's disease.

4. The method of claim 1 , wherein the disease is rheumatoid arthritis.

5. The method of claim 1 , wherein R 1 is C 1 to C 2 alkyl.

6. The method of claim 1 , wherein R 1 is methyl or trifluoromethyl.

7. The method of claim 1 , wherein R 1 is methyl.

8. The method of claim 1 , wherein R 2 is C 1 to C 4 alkyl.

9. The method of claim 1 , wherein R 2 is C 1 to C 3 alkyl.

10. The method of claim 9 , wherein R 2 is methyl or ethyl.

11. The method of claim 9 , wherein R 2 is isopropyl.

12. The method of claim 1 , wherein R 2 is C 3 to C 6 cycloalkyl.

13. The method of claim 12 , wherein R 2 is cyclopentyl.

14. The method of claim 1 , wherein R 2 is C 2 to C 4 alkenyl.

15. The method of claim 14 , wherein R 2 is allyl.

16. The method of claim 1 , wherein R 2 is C 2 to C 4 alkynyl.

17. The method of claim 16 , wherein R 2 is propargyl.

18. The method of claim 1 , wherein the compound is selected from the group consisting of:

(S)-2-(2-(diethylamino)-5-(N-ethyl-1,1,1-trifluoromethylsulfonamido)pyrimidin-4-ylamino)-3-(4-(pyrrolidine-1-carbonyloxy)phenyl)propanoic acid;

(S)-2-(2-(diethylamino)-5-(N-isopropylmethylsulfonamido)pyrimidin-4-ylamino)-3-(4-(pyrrolidine-1-carbonyloxy)phenyl)propanoic acid;

(S)-2-(5-(N-cyclopentylmethylsulfonamido)-2-(diethylamino)pyrimidin-4-ylamino)-3-(4-(pyrrolidine-1-carbonyloxy)phenyl)propanoic acid;

(S)-2-(2-(diethylamino)-5-(N-methylmethylsulfonamido)pyrimidin-4-ylamino)-3-(4-(pyrrolidine-1-carbonyloxy)phenyl)propanoic acid;

(S)-2-(2-(diethylamino)-5-(N-(prop-2-ynyl)methylsulfonamido)pyrimidin-4-ylamino)-3-(4-(pyrrolidine-1-carbonyloxy)phenyl)propanoic acid;

(S)-2-(2-(diethylamino)-5-(N-ethylmethylsulfonamido)pyrimidin-4-ylamino)-3-(4-(pyrrolidine-1-carbonyloxy)phenyl)propanoic acid;

(S)-2-(5-(N-allylmethylsulfonamido)-2-(diethylamino)pyrimidin-4-ylamino)-3-(4-(pyrrolidine-1-carbonyloxy)phenyl)propanoic acid; (S)-2-(2-(diethylamino)-5-(N-ethylbutylsulfonamido)pyrimidin-4-ylamino)-3-(4-(pyrrolidine-1-carbonyloxy)phenyl)-propanoic acid;

(S)-2-(5-(3-chloro-N-ethylpropylsulfonamido)-2-(diethylamino)-pyrimidin-4-ylamino)-3-(4-(pyrrolidine-1-carbonyloxy)phenyl)propanoic acid;

(S)-2-(5-(3-chloro-N-methylpropyl-sulfonamido)-2-(diethylamino)pyrimidin-4-ylamino)-3-(4-(pyrrolidine-1-carbonyloxy)phenyl)propanoic acid;

(S)-2-(2-(diethylamino)-5-(N-ethyl-3,3,3-trifluoropropylsulfonamido)-pyrimidin-4-ylamino)-3-(4-(pyrrolidine-1-carbonyloxy)phenyl)propanoic acid;

(S)-2-(2-(diethylamino)-5-(N-ethylpropylsulfonamido)pyrimidin-4-ylamino)-3-(4-(pyrrolidine-1-carbonyloxy)phenyl)-propanoic acid; and

(S)-2-(2-(diethylamino)-5-(N-ethyl-2-methylpropylsulfonamido)pyrimidin-4-ylamino)-3-(4-(pyrrolidine-1-carbonyloxy)-phenyl)propanoic acid;

and pharmaceutically acceptable salts or esters, thereof.

19. The method of claim 1 , wherein the disease is multiple sclerosis.

20. The method of claim 1 , wherein the disease is tumor metastasis.

21. The method of claim 1 , wherein the disease is graft versus host disease.

22. The method of claim 1 , wherein the disease is organ or tissue rejection.

23. The method of claim 1 , wherein the disease is ulcerative colitis.

24. The method of claim 1 , wherein the disease is inflammatory bowel disease.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2010
From: SMITH, JENIFER LEA; SEMKO, CHRISTOPHER; XU, YING-ZI; KONRADI, ANDREI W.
To: ELAN PHARMACEUTICALS, INC.
Reel/Frame 024994/0974 →